Wall Street analyst estimates for Inotiv, Inc. (NOTV): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-05 | $-0.47 | ||
| 2026-05-11 | $-0.94 | $-0.64 | -48.0% |
| 2026-02-09 | $-0.72 | $-0.64 | -12.9% |
| 2025-12-03 | $-0.14 | $-0.46 | +69.6% |
| 2025-08-06 | $-0.12 | $-0.15 | +20.0% |
| 2025-05-07 | $-0.18 | $-0.24 | +25.0% |
| 2025-02-05 | $-0.42 | $-0.42 | +0.0% |
| 2024-12-03 | $-0.16 | $-0.91 | +82.4% |
Valuation Ratios
| Price / Book | 0.04 |
| EV / EBITDA | 46.61 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.4M | $24.2M | $26.3M | $43.6M | $60.5M | $89.6M | $547.7M | $572.4M | $490.7M | $513.0M |
| Cost of Revenue | $16.0M | $16.5M | $18.2M | $30.7M | $42.2M | $59.4M | $390.4M | $407.0M | $379.6M | $448.0M |
| Gross Profit | $4.4M | $7.7M | $8.1M | $12.9M | $18.2M | $30.2M | $157.2M | $165.4M | $111.2M | $65.1M |
| Research & Development | $496000 | $465000 | $596000 | $627000 | $950000 | $405000 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $6.0M | $6.0M | $7.5M | $12.4M | $20.4M | $33.9M | $99.1M | $127.3M | $97.9M | $92.2M |
| Operating Expenses | $6.5M | $6.4M | $8.1M | $13.1M | $21.3M | $35.8M | $184.7M | $246.9M | $197.6M | $96.0M |
| Operating Income | -$3.0M | $1.3M | $14000 | -$153000 | -$3.1M | $1.5M | -$27.4M | -$81.5M | -$86.4M | -$30.9M |
| EBITDA | -$1.3M | $3.0M | $1.9M | $2.6M | $1.0M | $15.4M | -$273.4M | -$26.5M | -$26.8M | $24.8M |
| Interest Expense | $399000 | $375000 | $274000 | $642000 | $1.5M | $1.7M | $29.7M | $43.0M | $46.9M | $56.6M |
| Pre-tax Income | -$3.2M | $908000 | -$254000 | -$786000 | -$4.5M | $6.1M | -$352.4M | -$124.2M | -$130.8M | -$87.8M |
| Income Tax | -$14000 | $24000 | -$60000 | $4000 | $147000 | -$4.8M | -$15.2M | -$19.3M | -$21.9M | -$19.1M |
| Net Income | -$3.2M | $884000 | -$194000 | -$790000 | -$4.7M | $10.9M | -$337.3M | -$105.1M | -$108.4M | -$68.6M |
| EPS | $-0.40 | $0.11 | $-0.02 | $-0.08 | $-0.43 | $0.83 | $-13.85 | $-4.10 | $-4.19 | $-2.11 |
| EPS (Diluted) | $-0.40 | $0.10 | $-0.02 | $-0.08 | $-0.43 | $0.79 | $-13.85 | $-4.10 | $-4.19 | $-2.11 |
| Shares Outstanding (Diluted) | $8.1M | $8.7M | $8.8M | $10.4M | $10.9M | $13.9M | $24.4M | $25.6M | $25.9M | $32.5M |
Price
| Price | $0.08 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BDSX · BEAT · BIAF · CELU · FGEN · KZR · QNTM
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NOTV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks